March 10 (Reuters) - Valeant Pharmaceuticals (NYSE:VRX) International
Inc:
* Valeant issues statement responding to the March 10th
letter from the House Oversight Committee
* Says declined to produce documents to oversight committee
covered by the attorney-client privilege
* Says preparing a log for Oversight Committee detailing
what documents are being withheld under that privilege
* Says produced more than 78,000 pages of documents to House
Oversight Committee
* "We have cooperated with the Committee's review from
beginning and look forward to providing them with the log,
pursuant to their request"
Source text
Further company coverage: VRX.TO